This finding enabled the use of the first clinically relevant chemical inhibitor of PARP, olaparib, which spares normal HR-proficient cells while specifically targeting HRD tumor cells to undergo enhanced DNA damage-induced cell death [64,65]. This evidence concerns the gene PARP1 and neoplasm.